Download MendeleyDesign, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) alpha / gamma / delta Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.
Boubia, B., Poupardin, O., Barth, M., Binet, J., Peralba, P., Mounier, L., Jacquier, E., Gauthier, E., Lepais, V., Chatar, M., Ferry, S., Thourigny, A., Guillier, F., Llacer, J., Amaudrut, J., Dodey, P., Lacombe, O., Masson, P., Montalbetti, C., Wettstein, G., Luccarini, J.M., Legendre, C., Junien, J.L., Broqua, P.(2018) J Med Chem 61: 2246-2265
- PubMed: 29446942
- DOI: https://doi.org/10.1021/acs.jmedchem.7b01285
- Primary Citation of Related Structures:
6ENQ - PubMed Abstract:
Here, we describe the identification and synthesis of novel indole sulfonamide derivatives that activate the three peroxisome proliferator activated receptor (PPAR) isoforms. Starting with a PPARα activator, compound 4, identified during a high throughput screening (HTS) of our proprietary screening library, a systematic optimization led to the discovery of lanifibranor (IVA337) 5, a moderately potent and well balanced pan PPAR agonist with an excellent safety profile. In vitro and in vivo, compound 5 demonstrated strong activity in models that are relevant to nonalcoholic steatohepatitis (NASH) pathophysiology suggesting therapeutic potential for NASH patients.
Organizational Affiliation:
Inventiva , 50 rue de Dijon , 21121 Daix , France.
